Dr. Lee M. Krug
A graduate of the Washington University (St. Louis) School of Medicine, Dr. Lee M. Krug, MD, is a member of the Department of Thoracic Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. Board certified in internal medicine and medical oncology, Krug is considered an expert on malignant pleural mesothelioma.
Also educated at Johns Hopkins University in Baltimore, where he completed his internship, Krug is the Director of the Mesothelioma Program at MSKCC and, as such, is responsible for leading a multi-disciplinary team of doctors, scientists, and support staff, all working together to find new and better treatments for those dealing with this aggressive, asbestos-caused cancer.
Besides mesothelioma, Dr. Krug has a clinical interest in small cell lung cancer and other pulmonary neuroendocrine tumors as well as non-small cell lung cancer, and he continuously participates in clinical trials that test novel drugs and treatments for these diseases. Recently, he led a national study that analyzed the use of chemotherapy, surgery, and radiation for patients who were diagnosed with early stage mesothelioma. Krug also indicates a keen interest in therapies that are designed to enhance the immune system so that it will recognize and attack specific molecules found in cancer cells, and has worked with vaccines intended to fight certain kinds of lung cancer.
A recipient of a career development award from the American Society of Clinical Oncology for his work on vaccines for small cell lung cancer, Dr. Krug currently serves on the scientific advisory board of the Mesothelioma Applied Research Foundation. He is a published author and many of his articles have appeared in prestigious peer-reviewed journals.